People: Oncolytics Biotech Inc (ONCY.O)

ONCY.O on Consolidated Issue listed on NASDAQ Capital Market

1.60USD
16 Apr 2014
Price Change (% chg)

$0.10 (+6.67%)
Prev Close
$1.50
Open
$1.50
Day's High
$1.60
Day's Low
$1.50
Volume
351,668
Avg. Vol
506,286
52-wk High
$3.50
52-wk Low
$1.40

Search Stocks

Summary

Name Age Since Current Position

Bradley Thompson

1999 Executive Chairman of the Board, President, Chief Executive Officer

Kirk Look

2012 Chief Financial Officer

Matthew Coffey

2011 Chief Operating Officer, Director

George Gill

2002 Senior Vice President - Clinical and Regulatory Affairs

Alan Tuchman

66 2012 Chief Medical Officer, Senior Vice President - Medical and Clinical Affairs

Mary Dillahunty

2007 Vice President - Intellectual Property

Robert Schultz

2000 Lead Independent Director

Wayne Pisano

2013 Director

Jim Dinning

60 2004 Independent Director

Edwin Levy

2006 Independent Director

J. Mark Lievonen

2004 Independent Director

Fred Stewart

1999 Independent Director

Ger van Amersfoort

2006 Independent Director

Nick Hurst

IR Officer

Biographies

Name Description

Bradley Thompson

Dr. Bradley G. Thompson is an Executive Chairman of the Board, President, Chief Executive Officer of Oncolytics Biotech Inc., since April 21, 1999.

Kirk Look

Mr. Kirk J. Look is Chief Financial Officer of Oncolytics Biotech Inc. effective November 12, 2012. Mr. Look has served as Oncolytics' Controller since 2003 and has been the Chief Financial Officer of Oncolytics Biotech (U.S.) Inc. since 2009. Prior to joining Oncolytics, Mr. Look held senior audit roles with Ernst & Young LLP in both North and South America over an eight year period. He holds a Bachelor of Commerce degree from the University of Calgary and is a Chartered Accountant.

Matthew Coffey

Dr. Matthew C. Coffey is Chief Operating Officer, Director of Oncolytics Biotech Inc. He has been Chief Operating Officer of the Corporation since December 2008. Since April 1999 to December 2008, Dr. Coffey held other senior management positions with the Company and is a co-founder of Oncolytics.

George Gill

Dr. George M. Gill is Senior Vice President - Clinical and Regulatory Affairs of Oncolytics Biotech Inc. Dr. Gill has been a consultant in clinical research and regulatory affairs to the pharmaceutical and biotechnology industries since he retired from Ligand Pharmaceuticals in 1999. During his 38 years in the industry, he also served in senior executive positions with ICI Pharmaceuticals (now AstraZeneca), Bristol-Myers Squibb, and Hoffmann-La Roche. Dr. Gill holds a B.Sc. in chemistry from Dickinson College in Pennsylvania and an M.D. from the School of Medicine of the University of Pennsylvania in Philadelphia.

Alan Tuchman

Dr. Alan J. Tuchman is Chief Medical Officer, Senior Vice President - Medical and Clinical Affairs of Oncolytics Biotech Inc., since September 28, 2012. Dr. Tuchman is Clinical Professor of Neurology at New York Medical College and the author of over thirty scientific papers and book chapters. He is in the private practice of Neurology in Manhattan and consults to a number of biotechnology and investment firms. He has served as a partner of Xmark Opportunity Partners and as Executive Chairman of Neurophysics, Inc. He was previously the President of the Epilepsy Society of Southern New York as well as Vice Dean for Clinical Affairs at New York Medical College. Dr. Tuchman received his MD degree from the University of Cincinnati, College of Medicine, and completed his Neurology Residency at the Mt Sinai School of Medicine. Dr. Tuchman received his MBA from Columbia University.

Mary Dillahunty

Ms. Mary Ann Dillahunty is Vice President - Intellectual Property of Oncolytics Biotech Inc., since 2007. Prior to joining Oncolytics, Ms. Dillahunty was a principal in the law firm of Fish & Richardson, a intellectual property firm in the U.S.

Robert Schultz

Mr. Robert B. Schultz is Lead Independent Director of Oncolytics Biotech Inc., since June 30, 2000. He is former Chairman and Director of Rockwater Capital Corporation, formerly McCarvill Corporation (a financial services company) from 2001 to 2007. Mr. Schultz has held a variety of senior positions, and has participated on various industry-related boards and committees including Director and Chairman of the Investment Dealers Association of Canada.

Wayne Pisano

Jim Dinning

Mr. James F. Dinning is an Independent Director of Oncolytics Biotech Inc., since March 24, 2004. He is Chair of Western Financial Group since September 2004. Mr. Dinning was Executive Vice President of TransAlta Corporation (power generation and wholesale marketing company) from 1997 to 2004. Mr. Dinning is the Chair of Export Development Canada and Canada West Foundation and serves as a director of other public and private companies. He is the Chancellor of the University of Calgary.

Edwin Levy

Dr. Edwin Levy is an Independent Director of Oncolytics Biotech Inc., since May 17, 2006. He is Adjunct professor at the W. Maurice Young Centre for Applied Ethics at the University of British Columbia since retiring from QLT Inc., in late 2002.

J. Mark Lievonen

Mr. J. Mark Lievonen is an Independent Director of Oncolytics Biotech Inc., since April 5, 2004. He is President of Sanofi Pasteur Limited, a vaccine development, manufacturing and marketing company, since October 1998. Mr. Lievonen serves on a number of industry and not-for-profit boards including Rx&D, BIOTECanada, the Ontario Institute for Cancer Research and York University, and is a past Chair of BIOTECanada and the Ontario Genomics Institute.

Fred Stewart

Mr. Fred A. Stewart is an Independent Director of Oncolytics Biotech Inc., since August 27, 1999. He is former practising lawyer in Calgary; President of Fred Stewart & Associates Inc., consultant in commercialization of technology. Mr Stewart has served in a number of positions of corporate governance, in both private and public organizations.

Ger van Amersfoort

Mr. Ger J. van Amersfoort is an Independent Director of Oncolytics Biotech Inc., since June 15, 2006. He is President and Chief Executive Officer of Novartis Canada, a pharmaceutical company, until his retirement in 2001.

Nick Hurst

Basic Compensation

Options Compensation

Name Options Value

Bradley Thompson

1,070,160 618,960

Kirk Look

0 0

Matthew Coffey

874,433 538,231

George Gill

197,000 54,000

Alan Tuchman

0 0

Mary Dillahunty

116,667 0

Robert Schultz

0 0

Wayne Pisano

0 0

Jim Dinning

0 0

Edwin Levy

0 0

J. Mark Lievonen

0 0

Fred Stewart

0 0

Ger van Amersfoort

0 0

Nick Hurst

0 0
Search Stocks